Genomic Landscape in Prostate Cancer in a Latin American Population.

Autor:	Angel M; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina., Freile B; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina., Rodriguez A; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina., Cayol F; Hospital Italiano de Buenos Aires, CABA, Argentina., Manneh Kopp R; Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia., Rioja P; Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú., Soule T; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina., Losco F; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina., Bernal Vaca L; Instituto Nacional De Cancerología (Colombia), Bogotá, Colombia., Penaloza JM; Centro Oncológico Integral, Neuquén, Argentina., Zapata Muñoz ML; Clínica Las Américas Medellín, Antioquia, Colombia., Neciosup SP; Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú., Sanchez RR; Hospital Militar Central, Buenos Aires, Argentina., Passarella C; Hospital Universitario Austral, Buenos Aires, Argentina., Guerreño E; Instituto Misionero del Cáncer, Misiones, Argentina., Farelluk D; Instituto Misionero del Cáncer, Misiones, Argentina., Maturana Leiva E; Instituto del Cáncer Red Salud, Santiago de Chile, Chile., Zarba M; Hospital Centro de Salud Zenón Santillán, Tucumán, Argentina., Bourlon MT; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México., Mora Pineda M; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, México., Sade JP; Instituto Alexander Fleming, Buenos Aires, Argentina.; FUCA, Buenos Aires, Argentina.
Jazyk:	angličtina
Zdroj:	JCO global oncology [JCO Glob Oncol] 2024 Sep; Vol. 10, pp. e2400072. Date of Electronic Publication: 2024 Sep 30.
DOI:	10.1200/GO.24.00072
Abstrakt:	Purpose: This study aims to describe genomic characteristics of patients with metastatic prostate cancer (mPC). Patients and Methods: This study is a retrospective, multicenter cohort study of patients with mPC and reports on genomic testing. Patients were included from 12 academic centers in five countries. Results: A total of 349 patients with PC were included in this study. Most patients (209, 59.9%) were de novo metastatic. Genomic analysis was performed in 233 (66.6%) patients in the metastatic castration-resistant prostate cancer (mCRPC) setting, and only 115 (32.8%) patients had a tumor evaluation in the metastatic hormone sensitive prostate cancer scenario. The evaluation of somatic and/or germline mutations was performed through multigene panel analyses in 290 (83.09%) patients, and next-generation sequencing of BRCA1 and BRCA2 genes was performed in 59 (16.91%) patients. Analyzing the mCRPC subgroup, with a median follow-up of 15.6 months (IQR, 14-19.06), the median progression-free survival (PFS) was not reached (NR) and the PFS at 16 months was 58.7% (95% CI, 50.8 to 67.8). When comparing patients with BRCA mutations with those who are not BRCA -mutated in the mCRPC scenario, the median PFS was NR (95% CI, 14 to NR) and 26.3 months (95% CI, 16.7 to 36.5; P = .2), respectively. Two of six patients with BRCA mutations were treated with targeted therapies (poly-ADP-ribose polymerase inhibitors). Conclusion: Our study, to the best of our knowledge, represents one of the larger data sets for somatic testing in patients with PC in Latin America (LATAM). It adds valuable information to the growing body of knowledge about the genomic landscape of advanced PC in real-world daily practice scenarios in LATAM countries, which are not always well-represented in large-scale randomized clinical trials.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu